Emerging in vitro tools to evaluate cytochrome P450 and transporter-mediated drug-drug interactions

Current Drug Discovery Technologies

Volumn 7, Issue 3, 2010, Pages 199-222

  Lu, Chuang ^a   Liao, Mingxiang ^a   Cohen, Lawrence ^a   Xia, Cindy Q ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Cytochromes P450; DDI prediction; Drug metabolism enzyme; Drug transporters; Drug drug interaction; In vitro tools

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; FURAFYLLINE; QUINIDINE; SULFAPHENAZOLE;

AREA UNDER THE CURVE; CELL STRAIN CACO 2; CORRELATION ANALYSIS; DRUG INTERACTION; DRUG METABOLISM; DRUG TRANSPORT; ENZYME ACTIVITY; FOOD AND DRUG ADMINISTRATION; GENETIC TRANSFECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IC 50; IN VITRO STUDY; LIVER CELL; LIVER MICROSOME; NONHUMAN; OOCYTE; PRIORITY JOURNAL; REVIEW; YEAST;

EID: 78649590443     PISSN: 15701638     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016310793180549     Document Type: Review

References (136)

1. FDA. Drug interaction studies - study design, data analysis, and implications for dosing and labeling 2006. http://WWW.FDA.gov/ cder/guidence/6695dft.htm, 2006.
2. Hoing PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole: Pharmacokinetics and electrocardiographic consequences. JAMA 1993; 269: 1513-9.
3. Markham MA, Wagstaff AJ. Fexofenadine. Drugs 1998; 55: 269-74.
4. Abdel-Aziz MT, Wiliams KI. Metabolism of radioactive 17aethynylestradiol by women. Steroids 1970; 15: 695-710.
5. Li AP, Hartman NR, Lu C, Collins JM, Strong JM.Effects of cytochrome P450 inducers on 17a-ethynylestradiol (EE2) conjugation in primary human hepatocytes. Br J Clin Pharmacol 1999; 48: 733-42.
6. Back DJ, Breckenridge AM, Orawford FE, et al. The effect of rifampicin on the Pharmacokinetics of ethynyestradiol in women. Contraception 1980; 21: 255-81.
7. Bachmann KA. Inhibition constants, inhibitor concentrations and the prediction of inhibitory drug drug interaction: Pitfalls, progress and promise. Curr Drug Metab 2006; 7: 1-14.
8. Xia CQ, Milton MN, Gan LS. Evaluation of drug-transporter interactions using in vitro and in vivo models. Curr Drug Metab 2007; 8: 341-63.
9. Zhang L, Reynolds KS, Zhao P, Huang S-M. Drug interactions evaluation: An integrated part of risk assessment of therapeutics. Toxicol Appl Pharmacol 2010; 243(2): 134-45. Epub 2010 Jan 4.
10. Clarke SE. In vitro assessment of human cytochrome P450. Xenobiotica 1998; 28: 1167-202.
11. Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: Studies on amitriptyline as a model substrate. J Pharmacol Exp Ther 2001; 297(1): 326-37.
12. Uttamsingh V, Lu C, Miwa G, Gan LS. Relative contributions of the five major human Cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor Bortezomib. Drug Metab Dispos 2005; 33: 1723-8.
13. Crespi CL, Penman BW. Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions. Adv Pharmacol 1997; 43: 171-88.
14. Crespi CL. Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. Adv Drug Res 1995; 26: 179-235.
15. Venkatakrishnan K, Von Moltke LL, Court MH, Harmatz JS, Crespi CL, Greenblatt DJ. Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: Ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Dispos 2000; 8(12): 1493-504.
16. Emoto C, Murase S, Iwasaki K. Approach to the prediction of the contribution of major cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage. Xenobiotica 2006; 36(8): 671-83.
17. Protor NJ, Tucker GT, Rostami-Hodjegan A. Predicting drug clearance from recombinantly expressed CYPs: Intersystem extrapolation factors. Xenobiotica 2004; 34(2): 151-78.
18. Youdim KA, Zayed A, Dickins M, et al. Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction. Br J Clin Pharmacol 2008; 65(5): 680-92.
19. Emoto C, Iwasaki K. Approach to predict the contribution of cytochrome P450 enzymes to drug metabolism in the early drugdiscovery stage: The effect of the expression of cytochrome b5 with recombinant P450 enzymes. Xenobiotica 2007; 37(9): 986-99.
20. Lu C, Miwa GT, Prakash SR, Gan LS, Balani SK. A novel model for the prediction of drug-drug interactions in humans based on in vitro CYP phenotyping. Drug Metab Dispos 2007; 35: 79-85.
21. Lu C, Berg C, Prakash SR, Lee FW, Balani SK. Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma - part II. In vitro - in vivo correlation with fluconazole. Drug Metab Dispos 2008a; 36: 1255-60.
22. Lu C, Hatsis P, Berg C, Lee FW, Balani SK. Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma - part III. In vitro - in vivo correlation with ketoconazole. Drug Metab Dispos 2008b; 36: 1261-6.
23. Rodrigues AD. Prioritization of Clinical Drug Interaction Studies Using In vitro Cytochrome P450 Data: Proposed Refinement and Expansion of the "Rank Order" Approach. Drug Metab Lett 2007; 1: 31-5.
24. Fowler S, Zhang H. In vitro Evaluation of Reversible and Irreversible Cytochrome P450 Inhibition: Current Status on Methodologies and their Utility for Predicting Drug-Drug Interactions. AAPS J 2008; 10(2): 410-24.
25. Lin HL, Kent UM, Hollenberg PF. Mechanism-based inactivation of cytochrome P450 3A4by 17a-ethynylestradiol: Evidence fro heme destraction and covalent binding to protein. J Pharmacol Exp Ther 2002; 301: 160-7.
26. Grimm SW, Einolf HJ, Hall SD, et al. The conduct of in vitro studies to address time-dependent inhibition of drug metabolizing enzymes: A perspective of the pharmaceutical research and manufactures of America. Drug Metab Dispos 2009; 37: 1355-70.
27. Zhao P, Kunze KL, Lee CA. Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes. Drug Metab Dispos 2005; 33: 853-61.
28. McGinnity DF, Berry AJ, Kenny J, Grime K, Riley RJ. Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes. Drug Metab Dispos 2006; 34: 1291-300.
29. Xu L, Chen Y, Pan Y, Skiles GL, Shou M. Predictions human drug-drug interactions from time-dependent inactivation of CYP3A in primary hepatocytes using a population-based simulator. Drug Metab Dispos 2009; 37: 2330-9.
30. Zhao P, Lee CA, Kunze KL. Sequential metabolism is responsible for diltiazem-induced time-dependent loss of CYP3A. Drug Metab Dispos 2007; 35: 704-12.
31. Ohyama K, Nakajima, Suzuki M, Shimada N, Yamazaki H, Yokoi T. Inhibitiory effect of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: Prediction of in vivo drug. Br J Clin Pharmacol 2000; 49: 244-53.
32. Li P, Lu C, Daniels JS, Miwa G, Gan LS. CYP3A4 mediated timeand concentration-dependent CYP2D6 inhibition by a melanocortin receptor antagonist, Drug Metab Rev 2004; 36(Supplement1): 572.
33. Obach RS, Walsky RL, Venkatakrishnan K. Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 2007; 35: 246-55.
34. Berry LM, Zhao Z. An examination of IC50 and IC50-shift experiments in assessing time-dependent inhibition of CYP3A4, CYP2D6, and CYP2C9 in human liver microsomes. Drug Metab Lett 2008; 2: 51-9.
35. Burt HJ, Galtin A, Houston JB. IC50-based approches as an alternative method for assessment of time-dependent inhibition of CYP3A4. Xenobiotica 2010; 40: 331-43.
36. Li P, Lu C, Daniels JS, Labutti J, Miwa GT, Gan LS. A modified inhibition assay to identify CYP3A4 mechanism-based inhibitors. Drug Metab Rev 2005; 37 (Supplement 2): 254.
37. Segel HS. Enzyme kinetics. John Wiley & Son, Inc: New York, 1974.
38. Galetin A, Houston JB. Inhibition of Drug Metabolizing Enzymes in Gastrointestinal Tract and its Influence on the Drug-Drug Interaction Prediction, in Enzyme Inhibition in Drug Discovery and Development: The Good and The Bad, Lu C, Li AP, Eds. John Wiley & Sons, New York 2010.
39. Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A. Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 2007; 8: 676-84.
40. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A4. Annu Rev Pharmacol Toxicol 1998; 38: 389-430.
41. Galetin A, Ito K, Hallifax D, Houston JB. CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions. J Pharmacol Exp Ther 2005; 314: 180-90.
42. Stresser DM, Broudy MI, Ho T, et al. Highly selective inhibition of human CYP3A in vitro by azamulin and evidence that inhibition is irreversible. Drug Metab Dispos 2004; 32: 105-12.
43. Ito K, Brown H, Houston JB. Database analyses for prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 2004; 57: 473-86.
44. Blanchard N, Richert L, Coassolo P, Lave T. Qualitative and Quantitative assessment of drug-drug interaction potential in man, based on Ki, IC50 and inhibitor concentration. Curr Drug Metab 2004; 5: 147-56.
45. Cook CS, Berry LM, Burton E. Prediction of in vivo drug interaction with eplerenone in man from in vitro metabolic inhibition data. Xenobiotica 2004; 34: 215-28.
46. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM. The utility of in vitro cytochrome P450 inhibitioon data in the prediction of drug- drug interactions. J Pharmacol Exp Ther 2006; 316: 336-48.
47. Shitara Y, Li AP, Kato Y, et al. Function of uptake transporters for taurocholate and estradiol 17b-D-glucuronide in cryopreserved human hepatocytes. Drug Metab Pharmacokinet 2003; 18: 33-41.
48. Liu XR, LeCluyse EL, Brouwer KR, et al. Biliary excretion in primary rat hepatocytes culture in a collagen-sandwich configuration. Am J Physiol 1999; 277: G12-G21.
49. Salphati L, Benet LZ. Effect of ketoconazole on digoxin absorption and disposition in rat. Pharmocology 1998; 56: 308-13.
50. Achira M, Ito K, Suzuki H, Sugiyama Y. Comparative studies to determine the selective inhibitors fro P-Glycoprotein and cytochrome P4503A4. AAPS Pharmsci 1999; 1: 1-6.
51. Kodawara T, Yono I, Masuda S, et al. Interaction of azole antifungal agent with human p-glycoprotein expressed in a kidney epithelial cell line LLC-PK1. Yakubutsu Dotai 2001; 16: 5-11.
52. Soars MG, Gelboin HV, Krausz KW, Riley RJ. A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology. Br J Clin Pharmacol 2003; 55: 175-81.
53. Lu C, Balani SK, Qian MG, Prakash SR, Ducray PS,Von Moltke LL. Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug - drug interactions with MLN3897, a potent CCR1 antagonist. J Pharmacol Exp Ther 2010; 332: 562-8.
54. Yang J, Liao M, Shou M, et al. Cytochrome p450 turnover: Regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr Drug Metab 2008; 9: 384-94.
55. Fontana E, Dansette PM, Poli SM. Cytochrome P450 enzyme mechanism based inhibitions: Common sub-structures and reactivity. Drug Metab Rev 2005; 6: 413-54.
56. Zhou S, Chan E, Duan W, Huang, Chen YZ. Drug bioactivation, covalent binding to target proteins and toxicity relevance. Drug Metab Rev 2005; 1: 41-213.
57. Hewitt NJ, Lechón MJ, Houston JB, et al. Primary hepatocytes: Current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 2007; 39: 159-234
58. Chu V, Einolf HJ, Evers R, et al. In vitro and in vivo induction of cytochrome p450: A survey of the current practices and recommendations: A pharmaceutical research and manufacturers of america perspective. Drug Metab Dispos 2009; 37: 1339-54.
59. Mills JB, Rose KA, Sadagopan N, Sahi J, De Morais SM. Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line. J Pharmacol Exp Ther 2004; 309: 303-9.
60. Kenny JR, Chen L, McGinnity DF, et al. Efficient assessment of the utility of immortalized Fa2N-4 cells for cytochrome P450 (CYP) induction studies using multiplex quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) and substrate cassette methodologies. Xenobiotica 2008; 38: 1500-17.
61. Ripp SL, Mills JB, Fahmi OA, et al. Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. Drug Metab Dispos 2006; 34: 1742-8.
62. Hariparsad N, Carr BA, Evers R, Chu X. Comparison of immortalized Fa2N-4 cells and human hepatocytes as in vitro models for cytochrome P450 induction. Drug Metab Dispos 2008; 36: 1046-55.
63. McGinnity DF, Zhang G, Kenny JR, et al. Evaluation of Multiple in vitro Systems for Assessment of CYP3A4 Induction in Drug Discovery: Human Hepatocytes, Pregnane X Receptor Reporter Gene, and Fa2N-4 and HepaRG Cells. Drug Metab Dispos 2009; 37: 1259-68;
64. Guillouzo A, Corlu A, Aninat C, Glaise D, Morel F, Guguen- Guillouzo C. The human hepatoma HepaRG cells: A highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem Biol Interact 2007; 168: 66-73.
65. Lankas GR, Cartwright ME, Umbenhauer D. P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectininduced neurotoxicity. Toxicol Appl Pharmacol 1997; 143: 357-65.
66. Giacomini KM, Huang SM, Tweedie DJ, et al. For The International Transporter Consortium Membrane transporters in drug development. Nat Rev Drug Discov 2010; 9: 215-36.
67. Sarkadi B. PEM, Boucher RC, German UA, Scarborough GA. Expression of the human multidrug resistance cDNA insect cells generates a high activity drug-stimulated membrane ATPase. J Biol Chem 1992; 267: 4854-8.
68. Senior AE a-SMK, Urbatsch IL. ATP hydrolysis by multidrug resistance protein from Chinese hamster ovary cells. J Bioenerg Biomembr 1995; 27: 31-6.
69. Chang X-B, Hou Y-X, Riordan JR. Stimulation of ATPase activity of purified multidrug resistance-associated protein by nucleoside diphosphates. J Biol Chem 1998; 273: 23844-8.
70. Ozvegy C, Litman T, Szakacs G, Nagy Z, Bates S, Varadi A, Sarkadi B. Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun 2001; 285: 111-7.
71. Ozvegy C, Varadi A, Sarkadi B. Characterization of Drug Transport, ATP Hydrolysis, and Nucleotide Trapping by the Human ABCG2 Multidrug Transporter. Modulation of substrate specificity by a point mutation. J Biol Chem 2002; 277: 47980-90.
72. Druekes P. SR, Palm D. Photometric microtiter assay of inorganic phosphate in the presence of acid-labile organic phosphates. Anal Biochem 1995; 230: 173-7.
73. Promega. http://www.promega.com/tbs/tb341/tb341.pdf
74. Ramachandra M, Ambudkar SV, Gottesman MM, Pastan I, Hrycyna CA. Functional characterization of a glycine 185-to-valine substitution in human P-glycoprotein by using a vaccinia-based transient expression system. Mol Biol Cell 1996; 7: 1485-98.
75. Scarborough GA. Drug-stimulated ATPase activity of the human P-glycoprotein. J Bioenerg Biomembr 1995; 27: 37-41.
76. Polli JW, Wring SA, Humphreys JE, Serabjit-Singh CS. Rational Use of in vitro P-glycoprotein Assays in Drug Discovery. J Pharmacol Exp Ther 2001; 299: 620-8.
77. Xia CQ, Liu N, Miwa G, et al. Use of in vitro models to study interactions between the breast cancer resistant protein and its ligands. Drug Metab Rev 2004; 36: 53.
78. Garrigues A, Nugier J, Orlowski S, Ezan E. A High-Throughput Screening Microplate Test for the Interaction of Drugs with PGlycoprotein. Anal Biochem 2002; 305: 106-14.
79. Litman T, Zeuthen T, Skovsgaard T, Stein WD. Competitive, noncompetitive and cooperative interactions between substrates of Pglycoprotein as measured by its ATPase activity. Biochim Biophys Acta- Mol Basis Dis 1997; 1361: 169-76.
80. Xia CQ, Xiao G, Liu N, et al. Comparison of species differences of P-glycoproteins in beagle dog, rhesus monkey, and human using ATPase activity assays. Mol Pharm 2006; 3: 78-86.
81. Boulton DW, DeVane CL, Liston HL, Markowitz JS. In vitro Pglycoprotein affinity for atypical and conventional antipsychotics. Life Sci 2002; 71: 163-9.
82. Boyer JL, Meier PJ. Characterizing mechanisms of hepatic bile acid transport utilizing isolated membrane vesicles. Methods Enzymol 1990; 192: 517-33.
83. Meier PJ, Boyer JL. Preparation of basolateral (sinusoidal) and canalicular plasma membrane vesicles for the study of hepatic transport processes. Methods Enzymol 1990; 192: 534-45.
84. Tabas LB, Dantzig AH. A high-throughput assay for measurement of multidrug resistance protein-mediated transport of leukotriene C4 into membrane vesicles. Anal Biochem 2002; 310: 61-6.
85. Keppler D, Jedlitschky G, Leier I. Transport function and substrate specificity of multidrug resistance protein. Methods Enzymol 1998; 292: 607-16.
86. Horikawa M, Kato Y, Tyson CA, Sugiyama Y. The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: Probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. Drug Metab Dispos 2002; 17: 23-33.
87. Hirano M, Maeda K, Matsushima S, Nozaki Y, Kusuhara H, Sugiyama Y. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharm 2005; 68: 800-7.
88. Meier PJ, St. Meier-Abt A, Barrett C, Boyer JL. Mechanisms of taurocholate transport in canalicular and basolateral rat liver plasma membrane vesicles. Evidence for an electrogenic canalicular organic anion carrier. J Biol Chem 1984; 259: 10614-22.
89. Adachi Y, Kobayashi H, Kurumi Y, Shouji M, Kitano M, Yamamoto T. ATP-dependent taurocholate transport by rat liver canalicular membrane vesicles. Hepatology (Philadelphia, PA, United States) 1991; 14: 655-9.
90. Shapiro AB, Corder AB, Ling V. P-glycoprotein-mediated Hoechst 33342 transport out of the lipid bilayer. Eur J Biochem 1997; 250: 115-21.
91. Shapiro AB, Fox K, Lam P, Ling V. Stimulation of P-glycoproteinmediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site. Eur J Biochem 1999; 259: 841-50.
92. Ishizuka H, Konno K, Shiina T, et al. Species differences in the transport activity for organic anions across the bile canalicular membrane. J Pharmacol Exp Ther 1999; 290: 1324-30.
93. Ninomiya M, Ito K, Horie T. Functional analysis of dog multidrug resistance-associated protein 2 (MRP2) in comparison with rat MRP2. Drug Metab Dispos 2005; 33: 225-32.
94. Center MS, Zhu Q, Sun H. Mutagenesis of the putative nucleotidebinding domains of the multidrug resistance associated protein (MRP). Analysis of the effect of these mutations on MRP mediated drug resistance and transport. Cytotechnology 1998; 27: 61-9.
95. Volk EL, Schneider E. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res 2003; 63: 5538-43.
96. Sarkadi B, Homolya L, Hollo Z. Assay and reagent kit for evaluation of multi-drug resistance in cells, in: U.S., pp 17 pp., Cont.-inpart of U.S. 15,872,014. (Solvo Biotechnology, Hung.). Us. 2001.
97. Xia CQ, Yang JJ, Gan L-S. Breast cancer resistance protein in pharmacokinetics and drug-drug interactions. Expert Opin Drug Metab Toxicol 2005b; 1: 595-611.
98. Wang E-J, Casciano CN, Clement RP, Johnson WW. In vitro flow cytometry method to quantitatively assess inhibitors of Pglycoprotein. Drug Metab Dispos 2000; 28: 522-8.
99. Sigel E. Use of Xenopus oocytes for the functional expression of plasma membrane proteins. J Membr Biol 1990; 117: 201-21.
100. Simonson SG, Raza A, Martin PD, et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 2004; 76: 167-77.
101. Yamashiro W, Maeda K, Hirouchi M, Adachi Y, Hu Z, Sugiyama Y. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos 2006; 34: 1247-54
102. Makhey VD, Guo A, Norris DA, Hu P, Yan J, Sinko PJ. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm Res 1998; 15: 1160-7.
103. Gutmann H, Fricker G, Torok M, Michael S, Beglinger C, Drewe J. Evidence for different ABC-transporters in Caco-2 cells modulating drug uptake. Pharm Res 1999; 16: 402-7.
104. Taipalensuu J, Tornblom H, Lindberg G, et al. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther 2001; 299: 164-70.
105. Xia CQ, Liu N, Yang D, Miwa G, Gan L-S. Expression, localization, and functional characteristics of breast cancer resistance protein in Caco-2 cells. Drug Metab Dispos 2005a; 33: 637-43.
106. Calcagno AM, Ludwig JA, Fostel JM, Gottesman MM, Ambudkar SV. Comparison of drug transporter levels in normal colon, colon cancer, and Caco-2 cells: Impact on Drug Disposition and Discovery. Mol Pharm 2006; 3: 87-93.
107. Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 1991; 175: 880-5.
108. Gan L, Moseley M, Khosla B, et al. CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells. Drug Metab Dispos 1996; 24: 344-9.
109. Cummins CL, Jacobsen W, Benet LZ. Unmasking the Dynamic Interplay between Intestinal P-Glycoprotein and CYP3A4. J Pharmacol Exp Ther 2002; 300: 1036-45.
110. Mouly SJ, Paine MF, Watkins PB. Contributions of CYP3A4, Pglycoprotein, and serum protein binding to the intestinal first-pass extraction of saquinavir. J Pharmacol Exp Ther 2004; 308: 941-8.
111. Muller J, Lips KS, Metzner L, et al. Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol 2005; 70: 1851-60.
112. Neuhoff S, Ungell A-L, Zamora I, Artursson P. pH-Dependent passive and active transport of acidic drugs across Caco-2 cell monolayers. Eur J Pharm Sci 2005; 25: 211-20.
113. Hirano M, Maeda K, Shitara Y, Sugiyama Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 2004; 311: 139-46.
114. Hoffmaster KA, Turncliff RZ, LeCluyse EL, Kim RB, Meier PJ, Brouwer KLR. P-glycoprotein expression, localization, and function in sandwich-cultured primary rat and human hepatocytes: Relevance to the hepatobiliary disposition of a model opioid peptide. Pharm Res 2004; 21: 1294-302.
115. + modulation to evaluate biliary excretion in sandwich-cultured rat hepatocytes. J Pharmacol Exp Ther 1999; 289: 1592-9.
116. Kemp DC, Zamek-Gliszczynski MJ, Brouwer KLR. Xenobiotics inhibit hepatic uptake and biliary excretion of taurocholate in rat hepatocytes. Toxicol Sci 2005; 83: 207-14.
117. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitors: Drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006; 112: 71-105
118. Liao MX, Raczynski AR, Chen M, et al. Inhibition of hepatic OATP by RNAi in sandwich-cultured human hepatocytes: An in vitro model to assess transporter-mediated drug-drug interactions. Drug Metab Dispos 2010; 38(9): 1612-22.
119. Backman JT, Kyrklund C, NeuVonen M, NeuVonen PJ. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 2002; 72: 685-91.
120. Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)- mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: Analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 2004; 311: 228-36.
121. Durr D, Stieger B, Kullak-Ublick GA, et al. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmarcol Ther 2000; 68: 598-604.
122. Fromm MF, Kaufmann HM, Fritz P, et al. The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol 2000; 157: 1575-80.
123. Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal Pglycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104: 147-53
124. Gurley BJ, Swain A, Williams DK, Barone G, Battu SK. Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: Comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol Nutr Food Res 2008; 52: 772-9.
125. Marchetti S, Mazzanti R, Beijnen JH, Schellens JH. Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist 2007; 12: 927-41
126. Westphal K, Weinbrenner A, Zschiesche M, et al. Induction of Pglycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interaction. Clin Pharmacol Ther 2000; 68: 345-55.
127. Zschiesche M, Lemma GL, Klebingat KJ, Franke G, Terhaag B, Hoffmann A. Stereoselective disposition of talinolol in man. J Pharm Sci 2002; 91: 303-11.
128. Hamman MA, Bruce MA, Haehner-Daniels BD, Hall SD. The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther 2001; 69: 114-21.
129. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 2001; 276: 14581-7.
130. Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996; 49: 311-8.
131. Thummel KE, Brimer C, Yasuda K, et al. Transcriptional control of intestinal cytochrome P-4503A by lalpha, 25-dihydroxy vitamin D3. Mol Pharmacol 2001; 60: 1399-406.
132. Mitin T, Von Moltke LL, Court MH, Greenblatt DJ. Levothyroxine up-regulates P-gp independent of the pregnane X receptor. Drug Metab Dispos 2004; 32: 779-82
133. Maier A, Zimmermann C, Beglinger C, Drewe J, Gutmann H. Effects of budesonide on P-glycoprotein expression in intestinal cell lines. Br J Pharmacol 2007; 150: 361-8.
134. Fardel O, Morel F, Guillouzo A. P-glycoprotein expression in human, mouse, hamster and rat hepatocytes in primary culture. Carcinogenesis 1993; 14: 781-3.
135. Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 2001; 7: 584-90.
136. Zhang L, Zhang YD, Strong JM, Reynolds KS, Huang SM. A regulatory viewpoint on transporter-based drug interactions. Xenobiotica 2008; 38: 709-24.